Exploring the protective mechanism of Huangqishengmaiyin against anthracycline-induced cardiotoxicity in breast cancer with concomitant gut microbiota modulation
5 affiliations
- 1Department of Breast Surgery, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China
- 2Fifth Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China
- 3First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China
- 4College of Basic Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi, China
- 5College of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China
Abstract
Objective: To elucidate the bioactive compounds and cardioprotective mechanism of Huangqishengmaiyin (HQSMY) against anthracycline-induced cardiotoxicity (AIC) in breast cancer with concomitant gut microbiota modulation.
Methods: Myocardial fibrosis was quantified using Masson's trichrome staining. Hematoxylin and eosin staining was used for general histopathological evaluation. Ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-Q Exactive HFX) was employed to comprehensively identify blood components in HQSMY. The regulatory effect of HQSMY on the gut microbiota of AIC mice was assessed by 16S rRNA microbial sequencing. Network pharmacology and molecular docking mapped the compound-target-pathway network. Western blot was performed to detect key proteins in the predicted pathways, including JAK1, STAT3, and HIF-1α.
Results: HQSMY reduced myocardial fibrosis rates, enhanced gut microbiota diversity, abundance and health indices. Meanwhile, HQSMY increased the abundance of anti-inflammatory bacteria like Bacteroidetes and restored normal metabolic pathways in multiple gut microbes, including glycolysis. 42 blood components were identified, exhibiting antioxidant, anti-inflammatory, and gut microbiota-regulating activities. Network pharmacology analysis revealed that the JAK-STAT and HIF-1 signaling pathways are key mechanisms. Enrichment analysis focused on energy metabolism and inflammatory response. Western blot results confirmed that HQSMY significantly downregulated JAK1 and HIF-1α protein expression; STAT3 was decreased without reaching statistical significance.
Conclusion: The components of HQSMY exhibit anti-inflammatory effects in myocardial tissue, meanwhile enhancing beneficial gut bacteria in intestine. The regulatory effect of HQSMY may be exerted through JAK-STAT and HIF-1 pathways, as confirmed by altered expression of key proteins in these pathways.
Related
- Genetic Susceptibility to Anthracycline-Induced Cardiotoxicity in Australian Pediatric Cancer Patients
- Late Anthracycline Cardiotoxicity Mimicking Arrhythmogenic Cardiomyopathy in a Young Adult
- Anthracycline Cardiotoxicity as Multicellular Network Failure: Cardiac Niche Reprogramming and Pathological Cell–Cell Communication
- Cardiotoxicity of Immune Checkpoint Inhibitors with Anthracycline Chemotherapy in Triple-Negative Breast Cancer.
- Dynamic Changes in Apolipoproteins During Anthracycline Therapy: An Exploratory Study of Potential Biomarkers of Cardiotoxicity in Breast Cancer Patients
BibTeX
@article{wang2026exploring,
title = {{Exploring the protective mechanism of Huangqishengmaiyin against anthracycline-induced cardiotoxicity in breast cancer with concomitant gut microbiota modulation}},
author = {Yixuan Wang and Yeying Jin and Jiali Han and Mingjia Ding and Haoqing Hou and Miaoyu Mei and Rui Yang},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.3389/fcvm.2026.1818551},
url = {https://doi.org/10.3389/fcvm.2026.1818551},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Exploring the protective mechanism of Huangqishengmaiyin against anthracycline-induced cardiotoxicity in breast cancer with concomitant gut microbiota modulation
AU - Yixuan Wang
AU - Yeying Jin
AU - Jiali Han
AU - Mingjia Ding
AU - Haoqing Hou
AU - Miaoyu Mei
AU - Rui Yang
PY - 2026
DA - 2026/10/12
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1818551
UR - https://doi.org/10.3389/fcvm.2026.1818551
AB - Objective: To elucidate the bioactive compounds and cardioprotective mechanism of Huangqishengmaiyin (HQSMY) against anthracycline-induced cardiotoxicity (AIC) in breast cancer with concomitant gut microbiota modulation. Methods: Myocardial fibrosis was quantified using Masson's trichrome staining. Hematoxylin and eosin staining was used for general histopathological evaluation. Ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-Q Exactive HFX) was employed to comprehensively identify blood components in HQSMY. The regulatory effect of HQSMY on the gut microbiota of AIC mice was assessed by 16S rRNA microbial sequencing. Network pharmacology and molecular docking mapped the compound-target-pathway network. Western blot was performed to detect key proteins in the predicted pathways, including JAK1, STAT3, and HIF-1α. Results: HQSMY reduced myocardial fibrosis rates, enhanced gut microbiota diversity, abundance and health indices. Meanwhile, HQSMY increased the abundance of anti-inflammatory bacteria like Bacteroidetes and restored normal metabolic pathways in multiple gut microbes, including glycolysis. 42 blood components were identified, exhibiting antioxidant, anti-inflammatory, and gut microbiota-regulating activities. Network pharmacology analysis revealed that the JAK-STAT and HIF-1 signaling pathways are key mechanisms. Enrichment analysis focused on energy metabolism and inflammatory response. Western blot results confirmed that HQSMY significantly downregulated JAK1 and HIF-1α protein expression; STAT3 was decreased without reaching statistical significance. Conclusion: The components of HQSMY exhibit anti-inflammatory effects in myocardial tissue, meanwhile enhancing beneficial gut bacteria in intestine. The regulatory effect of HQSMY may be exerted through JAK-STAT and HIF-1 pathways, as confirmed by altered expression of key proteins in these pathways.
SN - 2297-055X
ER -